Archived explainer. For the current picture see today's CAPR page.
CAPRICOR THERAPEUTIC (CAPR) is drawing unusual attention today. Our newswire has captured 5 stories on CAPR across 3 sources in the last 36 hours, with AI sentiment reading bearish (avg 31/100).
CAPR stock is moving sharply lower today, down nearly 66% over the last eight sessions, as growing skepticism about the FDA approval prospects for its drug candidate deramiocel intensifies. Analysts and insiders are raising concerns about the strength of the data supporting the drug’s efficacy in treating Duchenne Muscular Dystrophy cardiomyopathy. The FDA’s upcoming advisory committee meeting has become a focal point, with recent briefing documents casting doubt on the clinical trial analysis plan.
Capricor Therapeutics faces mounting pressure as several analysts downgrade the stock and highlight the elevated risk of regulatory rejection. Alliance Global and Roth Capital have both flagged the FDA advisory meeting as a potential hurdle, while B. Riley and Cantor have echoed concerns about the drug’s approval path. The company disclosed that the FDA briefing relies on an outdated analysis plan, further fueling uncertainty. Meanwhile, insider sales by key executives, including CFO Anthony Bergmann and EVP Karen Krasney, have added to investor unease.
Retail traders are showing mixed sentiment, with some on Reddit and Stocktwits expressing bullish conviction despite the sharp selloff. However, the broader market is reacting to the deteriorating fundamentals and regulatory headwinds.
Over the past eight trading days, CAPR has fallen from $19.44 to $6.57, a decline of 66.2%. The stock is now trading near the lower end of its 52-week range of $4.30 to $40.37. Unusual options activity has also been observed, with $5.0 million in call premium traded, including a notable $1.4 million print. Insiders have sold a total of $1.5 million in shares over the last 90 days, with no insider purchases recorded. The stock’s beta of 0.42 suggests it is less volatile than the broader market, but recent performance defies that trend.
Investors should closely monitor the FDA advisory committee meeting, the outcome of which could determine the near-term trajectory of CAPR. No earnings date was provided, but coverage breadth and analyst commentary will remain key indicators of market sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Alliance Global said that the upcoming FDA advisory committee meeting now appears to be an ‘uphill battle’ for Capricor.
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Capricor (CAPR) downgraded to Sell as FDA doubts deramiocel efficacy in DMD cardiomyopathy; approval risk, dilution concerns despite cash.
Capricor shares plunged ~65% after the FDA briefing deemed deramiocel
Wall Street turned more cautious, with Roth, B. Riley and Cantor flagging elevated approval risk.
More on CAPR: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CAPR move explainers: 2026-07-29 · 2026-07-28 · 2026-07-27